Arthroplasty, Replacement, KneeNCT07730216
Ultrasonographic Predictors of Adductor Canal Block Effectiveness in Total Knee Arthroplasty
An observational study of Arthroplasty, Replacement, Knee and Nerve Block Assessment, run by Konya City Hospital at 1 site in Turkey (Türkiye).
Trial summary
Total knee arthroplasty (TKA) is associated with substantial postoperative pain and opioid requirements, making effective multimodal analgesia essential for early mobilization, functional recovery, and reduction of opioid-related adverse events [1,2]. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Arthroplasty, Replacement, Knee, Nerve Block Assessment, Pain, Postoperative Arthroscopy
- What is being tested?
- Adductor Canal Block (ACB) Only
- Type of treatment
- Surgery or procedure
- How many people
- 623 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 9 Aug 2026to 13 Jul 2027
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Scheduled for elective primary unilateral total knee arthroplasty under spinal anesthesia
Who may be able to join
- Age ≥18 years
- Scheduled for elective primary unilateral total knee arthroplasty under spinal anesthesia
- American Society of Anesthesiologists (ASA) physical status I-III
Who cannot join
- Daily opioid use or chronic pain syndrome
- Diabetic or other clinically diagnosed peripheral neuropathy
- Coagulopathy
- Infection at the injection site
- Known allergy or hypersensitivity to local anesthetics
- Revision total knee arthroplasty
- Conversion from spinal anesthesia to general anesthesia during surgery
- General anesthesia as the planned anesthetic technique
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Konya City Hospital
Konya, Konya, 42090
Ömer Keklicek, 05399291702, drokeklicek@gmail.com
About this study
Total knee arthroplasty (TKA) is associated with substantial postoperative pain and opioid requirements, making effective multimodal analgesia essential for early mobilization, functional recovery, and reduction of opioid-related adverse events [1,2]. Adductor canal block (ACB) has become a key component of enhanced recovery after surgery (ERAS) protocols because it provides effective anterior knee analgesia while largely preserving quadriceps muscle strength [2-4]. However, analgesic efficacy after ACB remains variable, and some patients require rescue opioid analgesia despite technically successful block placement [5]. Although ultrasound guidance improves block accuracy, factors such as tissue depth, anatomical variations, saphenous nerve visibility, and injectate spread pattern may influence clinical outcomes [6,7]. Prospective evidence regarding the predictive value of these ultrasound-derived parameters for ACB analgesic failure remains limited. Therefore, this study aims to evaluate whether preoperative ultrasound-derived tissue and target parameters-including skin-to-target depth, subcutaneous fat thickness, muscle thickness, saphenous nerve visibility, and injectate spread pattern-can predict ACB analgesic failure and early postoperative analgesic outcomes following TKA.
- Being tested
- Adductor Canal Block (ACB) Only
- Keywords
- Adductor Canal Block, Total Knee Arthroplasty, Ultrasound, Postoperative Analgesia
- Medical subject headings
- Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Adductor Canal Block (ACB) OnlyProcedure or surgery
The adductor canal block (ACB) will be performed in the post-anesthesia care unit (PACU) after regression of spinal anesthesia.
What is being measured
The primary outcome is the main question the study is designed to answer.
ACB Failure
ACB analgesic failure will be defined as the requirement for rescue analgesia during the first 24 hours after block administration, with intravenous tramadol (1 mg/kg) administered to patients with an NRS pain score ≥4.
Measured: 0-24 hours
Secondary outcomes (2)
Secondary outcome
- Numeric Rating Scale (NRS) Pain Scores
NRS pain scores at rest and during a standardized movement (active 90° knee flexion) will be recorded at postoperative 1, 6, 12, and 24 hours.
Measured: 0-24 hour
Tramadol Consumption
- Total Tramadol Consumption
Total tramadol consumption (mg) during the first 24 hours following ACB administration will be recorded.
Measured: 0-24 Hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2026
- Study start9 Aug 2026
- Primary completion13 Jul 2027 (estimated)
- Study completion13 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Arthroplasty, Replacement, KneeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 623 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Konya City Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ömer Keklicek, Konya City Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07730216
- Sponsor's protocol ID
- 2026/235
- Status last verified
- Jul 2026
- First submitted
- 13 Jul 2026
- Last updated
- 12 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ultrasonographic Predictors of Adductor Canal Block Effectiveness in Total Knee Arthroplasty
- ClinicalTrials.gov ID
- NCT07730216
- Acronym / sponsor ID
- 2026/235
- Keywords
- Adductor Canal Block, Total Knee Arthroplasty, Ultrasound, Postoperative Analgesia
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 623 participants (estimated)
- Lead sponsor
- Konya City HospitalUniversity, hospital or other
- Study start
- 9 Aug 2026 (actual)
- Primary completion
- 13 Jul 2027 (estimated)
- Study completion
- 13 Jul 2027 (estimated)
- First posted
- 28 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Total knee arthroplasty (TKA) is associated with substantial postoperative pain and opioid requirements, making effective multimodal analgesia essential for early mobilization, functional recovery, and reduction of opioid-related adverse events [1,2]. Adductor canal block (ACB) has become a key component of enhanced recovery after surgery (ERAS) protocols because it provides effective anterior knee analgesia while largely preserving quadriceps muscle strength [2-4]. However, analgesic efficacy after ACB remains variable, and some patients require rescue opioid analgesia despite technically successful block placement [5]. Although ultrasound guidance improves block accuracy, factors such as tissue depth, anatomical variations, saphenous nerve visibility, and injectate spread pattern may influence clinical outcomes [6,7]. Prospective evidence regarding the predictive value of these ultrasound-derived parameters for ACB analgesic failure remains limited. Therefore, this study aims to evaluate whether preoperative ultrasound-derived tissue and target parameters-including skin-to-target depth, subcutaneous fat thickness, muscle thickness, saphenous nerve visibility, and injectate spread pattern-can predict ACB analgesic failure and early postoperative analgesic outcomes following TKA.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 12 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Scheduled for elective primary unilateral total knee arthroplasty under spinal anesthesia
Key inclusion criteria (3 listed)
- Age ≥18 years
- Scheduled for elective primary unilateral total knee arthroplasty under spinal anesthesia
- American Society of Anesthesiologists (ASA) physical status I-III
Key exclusion criteria (8 listed)
- Daily opioid use or chronic pain syndrome
- Diabetic or other clinically diagnosed peripheral neuropathy
- Coagulopathy
- Infection at the injection site
- Known allergy or hypersensitivity to local anesthetics
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Adductor Canal Block (ACB) OnlyThe adductor canal block (ACB) will be performed in the post-anesthesia care unit (PACU) after regression of spinal anesthesia. | Procedure or surgery | – |
Primary outcome
ACB Failure
Time frame: 0-24 hours
ACB analgesic failure will be defined as the requirement for rescue analgesia during the first 24 hours after block administration, with intravenous tramadol (1 mg/kg) administered to patients with an NRS pain score ≥4.
2 secondary outcomes
Secondary outcome
Time frame: 0-24 hour
Tramadol Consumption
Time frame: 0-24 Hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Arthroplasty, Replacement, Knee
RecruitingPhase 3
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
Venous Thromboembolism (VTE)
Recruiting
SII Levels Following iPACK Block With Adductor Canal Block in Knee Arthroplasty
Knee Osteoarthritis
Enrolling by invitationObservational study
Persona SoluTion PPS Femur PMCF
Rhematoid Arthritis, Osteo Arthritis of the Knee
Recruiting
ACB and iPACK Blocks With Intravenous Dexamethasone and Perineural Dexmedetomidine in Total Knee Arthroplasty
Knee Osteoarthritis
RecruitingPhase 3
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Symptomatic Venous Thromboembolism (VTE)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Arthroplasty, Replacement, Knee and Nerve Block Assessment, run by Konya City Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ömer Keklicek, Principal Investigator (+905399291702, drokeklicek@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ACB Failure (time frame: 0-24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2026.